Manufacturer of Controlled Substances; Notice of Registration, 28074 [E7-9617]

Download as PDF 28074 Federal Register / Vol. 72, No. 96 / Friday, May 18, 2007 / Notices Dated: May 10, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–9606 Filed 5–17–07; 8:45 am] DEPARTMENT OF JUSTICE BILLING CODE 4410–09–P By Notice dated November 2, 2006, and published in the Federal Register on November 8, 2006, (71 FR 65544), Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule II: Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration pwalker on PROD1PC71 with NOTICES By Notice dated December 14, 2006, and published in the Federal Register on December 22, 2006, (71 FR 77065– 77066), Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of 14– Hydroxymorphinone (9654), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substances in bulk as an intermediate for use in the production of another controlled substance. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Johnson Matthey Inc to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Johnson Matthey Inc to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–9617 Filed 5–17–07; 8:45 am] BILLING CODE 4410–09–P VerDate Aug<31>2005 17:06 May 17, 2007 Jkt 211001 Drug Schedule Nabilone (7379) ............................ Noroxymorphone (9668) .............. II II The company plans to manufacture the listed controlled substances in bulk for sales to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Johnson Matthey Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Johnson Matthey Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: May 14, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–9629 Filed 5–17–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated December 14, 2006, and published in the Federal Register on December 22, 2006, (71 FR 77065), PO 00000 Frm 00056 Fmt 4703 Sfmt 4703 Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Remifentanil (9739), a basic class of controlled substance listed in schedule II. The company plans on producing this item for sale to its customers, who are final dosage manufacturers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Johnson Matthey Inc to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Johnson Matthey Inc to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with State and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: May 9, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–9634 Filed 5–17–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated December 14, 2006, and published in the Federal Register on December 22, 2006, (71 FR 77065– 77066), Johnson Matthey Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West Deptford, New Jersey 08066, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of 14– Hydroxymorphinone (9654), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substances in bulk as an intermediate for use in the production of another controlled substance. E:\FR\FM\18MYN1.SGM 18MYN1

Agencies

[Federal Register Volume 72, Number 96 (Friday, May 18, 2007)]
[Notices]
[Page 28074]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-9617]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated December 14, 2006, and published in the Federal 
Register on December 22, 2006, (71 FR 77065-77066), Johnson Matthey 
Inc., Custom Pharmaceuticals Department, 2003 Nolte Drive, West 
Deptford, New Jersey 08066, made application by letter to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of 14-Hydroxymorphinone (9654), a basic class of 
controlled substance listed in schedule II.
    The company plans to manufacture the listed controlled substances 
in bulk as an intermediate for use in the production of another 
controlled substance.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Johnson Matthey Inc to manufacture the listed basic class of controlled 
substance is consistent with the public interest at this time. DEA has 
investigated Johnson Matthey Inc to ensure that the company's 
registration is consistent with the public interest. The investigation 
has included inspection and testing of the company's physical security 
systems, verification of the company's compliance with State and local 
laws, and a review of the company's background and history. Therefore, 
pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the 
above named company is granted registration as a bulk manufacturer of 
the basic class of controlled substance listed.

    Dated: May 14, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E7-9617 Filed 5-17-07; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.